Press

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Oct 4 • 5 min read

Quick Take: Dr. Inamdar is the recipient of multiple research and development awards for his work in clinical drug development. Cybin Inc. (NYSE:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as…

Mydecine Completes Spin-Out of U.S. Cannabis Assets

Oct 1 • 4 min read

Quick Take: The purpose of the transaction was the comply with U.S. Nasdaq listing requirements as well as London Stock Exchange requirements. Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has completed its previously announced spin-out transaction (the “Transaction”) of ALT…

Braxia Scientific Reports Encouraging Results of Ketamine Study

Sep 30 • 3 min read

Quick Take: The study shows significant reduction in depressive symptoms and suicidality. Braxia Scientific Corp, (CSE: BRAX) (OTC: BRAXF), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective…

HAVN Life Acquires Bennett’s Choice Patented Brain Health and Recovery Formulations

Sep 29 • 4 min read

Quick Take: The Acquisition will add more products to HAVN Life’s existing line of natural health products, with additional product launches planned in the near future. Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind is pleased…

BetterLife Pharma Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile

Sep 28 • 5 min read

Quick Take: BetterLife, an emerging biotechnology company with focuses on psychedelics and delivery technology, has enrolled the first patient in their COVID-19 alpha-2b trial. The trial will take place through BetterLife’s wholly owned subsidiary, Altum Pharmaceuticals. BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have enrolled…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435